Take from the rich, give to the poor.
If you had such a stellar therapy, and you couldn't get it past Editas, you'd go to Europe and partner with any number of a dozen other entities there that would be guaranteed to be interested (such as Novartis, which owns part of NTLA).
In short, if you want to sell a product, Editas gets right of first refusal to license from Broad, and only if they refuse would the startup be able to proceed to license. If you just want to use CRISPR for in house research, you have to license it; no idea if the fees are prohibitive.